Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated

DOI10.1002/SIM.9405zbMATH Open1547.62226MaRDI QIDQ6628617

Dean A. Follmann, Michael P. Fay, Craig Magaret

Publication date: 29 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

clinical trialCox regressionvaccineSARS-CoV-2sieve analysis

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy
• Mark-specific hazard ratio model with missing multivariate marks
• Incorporating founder virus information in vaccine field trials
• Covariance Analysis of Censored Survival Data Using Log-Linear Analysis Techniques
• The Analysis of Failure Times in the Presence of Competing Risks
• Assessing vaccine durability in randomized trials following placebo crossover

This page was built for publication: Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6628617)